1024583-33-2

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-bromobenzo[d]thiazole-6-carboxylate is used as a key intermediate in the synthesis of pharmaceutical compounds for its potential to enhance the biological activity of target molecules. Its unique structure allows for the development of new drugs with improved efficacy and selectivity.
Used in Agrochemical Industry:
In the agrochemical sector, methyl 2-bromobenzo[d]thiazole-6-carboxylate is utilized as a precursor in the production of pesticides and other agrochemicals. Its chemical properties contribute to the creation of effective compounds for pest control and crop protection, ensuring agricultural productivity and food security.
Used in Organic Synthesis:
Methyl 2-bromobenzo[d]thiazole-6-carboxylate serves as a valuable building block in organic synthesis, enabling the construction of a wide range of organic compounds with diverse applications. Its reactivity and structural features facilitate the synthesis of novel molecules for research and industrial applications.
Used in Material Science:
In the field of material science, methyl 2-bromobenzo[d]thiazole-6-carboxylate is employed in the development of advanced materials with specific properties. Its incorporation into polymers and other materials can lead to improved performance characteristics, such as enhanced stability, conductivity, or optical properties.
Used in Research and Development:
Methyl 2-bromobenzo[d]thiazole-6-carboxylate is utilized in research and development settings to explore its potential applications and properties. Scientists and researchers investigate its reactivity, stability, and interactions with other compounds to uncover new uses and optimize its performance in various applications.

Upstream product

• 66947-92-0 2-aminobenzo[d]thiazole-6-carboxylic acid methyl ester 
• 22514-58-5 2-bromobenzo[d]thiazole-6-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 619-45-4 4-methoxycarbonyl aniline 
• 93-85-6 2-aminobenzothiazole-6-carboxylic acid 

Downstream Products

• 22514-58-5 2-bromobenzo[d]thiazole-6-carboxylic acid 
• 1620069-92-2 C₂₇H₂₁N₃O₅S 
• 1620069-94-4 C₂₇H₂₀N₃O₅S^(1-)*Na⁽¹⁺⁾ 
• 1620074-46-5 C₂₈H₂₃N₃O₅S 

Relevant academic research and scientific papers

Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis

Farnesoid X receptor (FXR) plays a key role in bile acid homeostasis, inflammation, fibrosis, and metabolism of lipid and glucose and becomes a promising therapeutic target for nonalcoholic steatohepatitis (NASH) or other FXR-dependent diseases. The phase III trial results of obeticholic acid demonstrate that the FXR agonists emerge as a promising intervention in patients with NASH and fibrosis, but this bile acid-derived FXR agonist brings severe pruritus and an elevated risk of cardiovascular disease for patients. Herein, we reported our efforts in the discovery of a series of non-bile acid FXR agonists, and 36 compounds were designed and synthesized based on the structure-based drug design and structural optimization strategies. Particularly, compound 42 is a highly potent and selective FXR agonist, along with good pharmacokinetic profiles, high liver distribution, and preferable in vivo efficacy, indicating that it is a potential candidate for the treatment of NASH or other FXR-dependent diseases.

FXR receptor agonist

The present invention discloses an FXR receptor agonist, belongs to the technical field of medicine, and particularly relates to a compound represented by a formula (I), a pharmaceutically acceptablesalt, an ester or a stereoisomer thereof, wherein R, R, R, M, L, L1, W, A , B, Q, m and n are defined in the specification. The present invention further relates to a preparation method of the compound, a pharmaceutical preparation, and applications in preparation of drugs for treatment and/or prevention of nonalcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorder, diabetic complication, malignant tumors and other related diseases mediated by FXR receptors. The formula I is defined in the specification.

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS

Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1

The present invention is directed to substituted benzothiazole and benzoxazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.

Discovery of 2-amino-6-carboxamidobenzothiazoles as potent Lck inhibitors

A novel series of 2-amino-6-carboxamidobenzothiazole was discovered to have potent Lck inhibitory properties. A highly efficient chemistry was developed. Also described are the detailed SAR study and the BaF3 cell line profiling for this series.

BENZOTHIAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS

The invention provides compounds of formula (1 ) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of AIk, AbI, Aurora-A, B-Raf, Bcr-Abl, BRK, BIk, Bmx, c-Kit, c-RAF, cSRC. CSK, FLTl, Fms, Fyn, JAK2, KDR, Lck, Lyn, PDGFRα, PDGFRβ, PKCα. p38 (p38 MAP kinase, SAPK2α), Src, SIK, Syk, Tie2 and TrkB kinases. FORMULE (I)